VIPR1 and hepatocellular carcinoma: Vasoactive Intestinal Peptide Receptor 1 (VIPR1) expression is significantly reduced in human HCC tissues and is associated with advanced clinical stages, tumor growth, recurrence, and poor patient outcomes.